Leukemia cell lines exposed to tyrosine kinase inhibitors. (A) BCR-ABL–negative cell lines exposed to 1.0 μmol/L CGP57148B (A, HL60; B, U937; C, KG1; D, RPMI 8226; E, Jurkat). (B) BCR-ABL–positive cell lines exposed to 1.0 μmol/L CGP57148B (A, KCL22; B, SD1; C, KU812; D, LAMA84; E, KYO1; F, TOM1; G, K562; H, BV173; I, EM3; J, AR230). (C) HL60 (A), U937 (B), Jurkat (C), KG1 (D), SD1 (E), RPMI 8226 (F), and KCL22 (G) exposed to 10 μmol/L CGP57148B. (D) Exposure to 10 μmol/L AG490 and 10 μmol/L AG879.